Abstract 4364: Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancerAshna Talwar, Rajender R. Aparasu, Ashish A. Deshmukh et al.|Cancer Research|2023Cited by 3